Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease
View/ Open
Published Version
https://doi.org/10.1007/s40119-013-0015-2Metadata
Show full item recordCitation
Carreras, Edward T., and Jessica L. Mega. 2013. “Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease.” Cardiology and Therapy 2 (1): 85-96. doi:10.1007/s40119-013-0015-2. http://dx.doi.org/10.1007/s40119-013-0015-2.Abstract
Anticoagulation is needed for stroke prevention in patients with atrial fibrillation. Antiplatelet therapy is essential for the prevention of stent thrombosis and the reduction of cardiovascular events in patients who undergo coronary stenting and suffer acute coronary syndromes. When these conditions overlap, the individual antithrombotic strategies are commonly combined, and the efficacy benefit of triple oral antithrombotic therapy is assumed to outweigh the bleeding risk based on the available data. Recent studies have investigated this topic further, including the first randomized controlled trial to address this issue. This new evidence challenges previous assumptions and may have implications for future practice and investigation.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107432/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12717554
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)